1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES Redesign of the List • The 2021 Prohibited List is redesigned to improve navigation and usability. Specified Methods • M2.2 is now a Specified Method in accordance with Article 4.2.2 of the 2021 World Anti-Doping Code (the Code). Substances of Abuse • Article 4.2.3 of the Code defines Substances of Abuse as those “Prohibited Substances which are specifically identified as Substances of Abuse on the Prohibited List because they are frequently abused in society outside of the context of sport.” • Cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”) and tetrahydrocannabinol (THC) are designated as Substances of Abuse. • Other substances are currently under review and may be designated as Substances of Abuse in the future. 2021 Prohibited List 2 S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics • Transforming growth factor-beta (TGF-β) signalling inhibitors are now included with their full rather than abbreviated name. • IOX2 is added as an example of a hypoxia-inducible factor (HIF) activating agent. S3. Beta-2 Agonists • Inhaled vilanterol is now permitted up to the manufacturer’s maximum recommended dose. The dose is expressed as the metered dose of 25 micrograms which is equivalent to a delivered dose of 22 micrograms. • It is clarified that arformoterol and levosalbutamol are prohibited by adding them as examples. S4. Hormone and Metabolic Modulators • Sub-classes 4.2 and 4.3 were amalgamated to become anti-estrogenic substances (including selective estrogen receptor modulators (SERMs)). This clarification in terminology reflects that, for anti-doping purposes, all these substances act by a common mechanism of binding to estrogen receptors and blocking estrogen action. This clarification did not add or remove any substances from this category. S5. Diuretics and Masking Agents • The wording regarding the exception to allow the ophthalmic use of carbonic anhydrase inhibitors is clarified as “topical ophthalmic administration”. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES M2. Chemical and Physical Manipulation • As explained above, M2.2 is changed from a non-Specified to a Specified Method. PROHIBITED METHODS 3 S6. Stimulants • Examples of imidazole derivatives for topical use are added to the exceptions. These are brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline and xylometazoline. S9. Glucocorticoids • Additional examples of glucocorticoids are added to the List. The names of some existing examples are clarified to better reflect the active drug compound. • As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved, at its 14-15 September 2020 meeting, prohibiting all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This one-year period will allow, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new reporting values, and sports authorities to develop educational tools for Athletes, medical and support personnel, addressing the safe use of glucocorticoids for clinical purposes in anti-doping. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES P1. Beta-blockers • Nebivolol was added as an example. 4 Beta-2 Agonists: In and Out-of-Competition: • Any combination of beta-2 agonists was removed as the required prevalence data were obtained. • Findings for salmeterol and vilanterol below the Minimum Reporting Level are included in the Monitoring Program to better monitor their therapeutic use vs risk of abuse. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES Redesign of the List • The 2021 Prohibited List is redesigned to improve navigation and usability. Specified Methods • M2.2 is now a Specified Method in accordance with Article 4.2.2 of the 2021 World Anti-Doping Code (the Code). Substances of Abuse • Article 4.2.3 of the Code defines Substances of Abuse as those “Prohibited Substances which are specifically identified as Substances of Abuse on the Prohibited List because they are frequently abused in society outside of the context of sport.” • Cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”) and tetrahydrocannabinol (THC) are designated as Substances of Abuse. • Other substances are currently under review and may be designated as Substances of Abuse in the future. 2021 Prohibited List 2 S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics • Transforming growth factor-beta (TGF-β) signalling inhibitors are now included with their full rather than abbreviated name. • IOX2 is added as an example of a hypoxia-inducible factor (HIF) activating agent. S3. Beta-2 Agonists • Inhaled vilanterol is now permitted up to the manufacturer’s maximum recommended dose. The dose is expressed as the metered dose of 25 micrograms which is equivalent to a delivered dose of 22 micrograms. • It is clarified that arformoterol and levosalbutamol are prohibited by adding them as examples. S4. Hormone and Metabolic Modulators • Sub-classes 4.2 and 4.3 were amalgamated to become anti-estrogenic substances (including selective estrogen receptor modulators (SERMs)). This clarification in terminology reflects that, for anti-doping purposes, all these substances act by a common mechanism of binding to estrogen receptors and blocking estrogen action. This clarification did not add or remove any substances from this category. S5. Diuretics and Masking Agents • The wording regarding the exception to allow the ophthalmic use of carbonic anhydrase inhibitors is clarified as “topical ophthalmic administration”. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES M2. Chemical and Physical Manipulation • As explained above, M2.2 is changed from a non-Specified to a Specified Method. PROHIBITED METHODS 3 S6. Stimulants • Examples of imidazole derivatives for topical use are added to the exceptions. These are brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline and xylometazoline. S9. Glucocorticoids • Additional examples of glucocorticoids are added to the List. The names of some existing examples are clarified to better reflect the active drug compound. • As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved, at its 14-15 September 2020 meeting, prohibiting all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This one-year period will allow, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new reporting values, and sports authorities to develop educational tools for Athletes, medical and support personnel, addressing the safe use of glucocorticoids for clinical purposes in anti-doping. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES P1. Beta-blockers • Nebivolol was added as an example. 4 Beta-2 Agonists: In and Out-of-Competition: • Any combination of beta-2 agonists was removed as the required prevalence data were obtained. • Findings for salmeterol and vilanterol below the Minimum Reporting Level are included in the Monitoring Program to better monitor their therapeutic use vs risk of abuse. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2020 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2020 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) when administered exogenously, including but not limited to: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); 5-Androstenedione (androst-5-ene-3,17-dione); 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-Keto-DHEA; 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α- androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); S0 S1 Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol); Drostanolone; Epiandrosterone (3β-hydroxy-5α-androstan-17-one); Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3- one); Epitestosterone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylclostebol; Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone (19-nortestosterone); Norboletone; 3 Norclostebol (4-chloro-17β-ol-estr-4-en-3-one); Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Testosterone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyeth- ylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Cobalt; Daprodustat (GSK1278863); Molidustat (BAY 85-3934); Roxadustat (FG-4592); Vadadustat (AKB-6548); Xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) signalling inhibitors, e.g. Luspatercept; Sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). S2 4 2. Peptide Hormones and their Releasing Factors, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. Lenomorelin (ghrelin) and its mimetics, e.g. Anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. Alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin). 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF); and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tretoquinol (trimetoquinol); Tulobuterol; Vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. S3 5 HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5α-androst-2-en-17-ol); 2-Androstenone (5α-androst-2-en-17-one); 3-Androstenol (5α-androst-3-en-17-ol); 3-Androstenone (5α-androst-3-en-17-one); 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Bazedoxifene; Ospemifene; Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; Cyclofenil; Fulvestrant. 4. Agents preventing activin receptor IIB activation including, but not limited, to: Activin A-neutralizing antibodies; Activin receptor IIB competitors such as: Decoy activin receptors (e.g. ACE-031); Anti-activin receptor IIB antibodies (e.g. Bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g. Follistatin, myostatin propeptide); Myostatin-neutralizing antibodies (e.g. Domagrozumab, S4 landogrozumab, stamulumab). 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. Bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. Tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. Dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. S5 6 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. Haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. Addition of proteases to Sample. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M1 M2 GENE AND CELL DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. 3. The use of normal or genetically modified cells. M3 7 IN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamfetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants: Including, but not limited to: 3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-2-amine (1,3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimetamfetamine (dimethylamphetamine); Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octodrine (1,5-dimethylhexylamine); Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 8 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for dermatological, nasal or ophthalmic use and those stimulants included in the 2020 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2020 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC Except: • Cannabidiol. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. S7 S8 S9 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Metipranolol; Atenolol; Metoprolol; Betaxolol; Nadolol; Bisoprolol; Oxprenolol; Bunolol; Pindolol; Carteolol; Propranolol; Carvedilol; Sotalol; Celiprolol; Timolol. Esmolol; P1 www.wada-ama.org

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2020 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2020 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) when administered exogenously, including but not limited to: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); 5-Androstenedione (androst-5-ene-3,17-dione); 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-Keto-DHEA; 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α- androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); S0 S1 Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol); Drostanolone; Epiandrosterone (3β-hydroxy-5α-androstan-17-one); Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3- one); Epitestosterone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylclostebol; Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone (19-nortestosterone); Norboletone; 3 Norclostebol (4-chloro-17β-ol-estr-4-en-3-one); Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Testosterone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyeth- ylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Cobalt; Daprodustat (GSK1278863); Molidustat (BAY 85-3934); Roxadustat (FG-4592); Vadadustat (AKB-6548); Xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) signalling inhibitors, e.g. Luspatercept; Sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). S2 4 2. Peptide Hormones and their Releasing Factors, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. Lenomorelin (ghrelin) and its mimetics, e.g. Anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. Alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin). 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF); and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tretoquinol (trimetoquinol); Tulobuterol; Vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. S3 5 HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5α-androst-2-en-17-ol); 2-Androstenone (5α-androst-2-en-17-one); 3-Androstenol (5α-androst-3-en-17-ol); 3-Androstenone (5α-androst-3-en-17-one); 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Bazedoxifene; Ospemifene; Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; Cyclofenil; Fulvestrant. 4. Agents preventing activin receptor IIB activation including, but not limited, to: Activin A-neutralizing antibodies; Activin receptor IIB competitors such as: Decoy activin receptors (e.g. ACE-031); Anti-activin receptor IIB antibodies (e.g. Bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g. Follistatin, myostatin propeptide); Myostatin-neutralizing antibodies (e.g. Domagrozumab, S4 landogrozumab, stamulumab). 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. Bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. Tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. Dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. S5 6 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. Haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. Addition of proteases to Sample. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M1 M2 GENE AND CELL DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. 3. The use of normal or genetically modified cells. M3 7 IN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamfetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants: Including, but not limited to: 3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-2-amine (1,3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimetamfetamine (dimethylamphetamine); Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octodrine (1,5-dimethylhexylamine); Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 8 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for dermatological, nasal or ophthalmic use and those stimulants included in the 2020 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2020 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC Except: • Cannabidiol. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. S7 S8 S9 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Metipranolol; Atenolol; Metoprolol; Betaxolol; Nadolol; Bisoprolol; Oxprenolol; Bunolol; Pindolol; Carteolol; Propranolol; Carvedilol; Sotalol; Celiprolol; Timolol. Esmolol; P1 www.wada-ama.org

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2022 Prohibited List S1. Anabolic Agents • Tibolone is transferred from S1.2 to S1.1 because it has clinical effects as a synthetic oral androgen mediated by effects on the androgen receptor, largely due to its conversion to the delta-4 tibolone metabolite, which is a potent androgen. • Osilodrostat, a CYP11B1 inhibitor, is added to S1.2 due to its off-target increase in circulating testosterone. S3. Beta-2 Agonists • The daily dosing time intervals for salbutamol are modified to 600 micrograms over 8 hours starting from the time any dose is taken (previously 800 micrograms over 12 hours). This is to reduce the risk of any potential Adverse Analytical Finding arising after high doses are taken at once. • The total permitted daily dose remains at 1600 micrograms over 24 hours. A Therapeutic Use Exemption (TUE) should be sought for doses in excess of these limits. • For example, an athlete could take 600 micrograms in the first 8 hours, 600 micrograms in the following 8 hours, and 400 micrograms in the remaining 8 hours of the day, without the need for a TUE. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. Non-approved Substances • BPC-157 is now prohibited under S0 following a recent re-evaluation and added as an example. S2. Peptide hormones, growth factors, related substances and mimetics • Lonapegsomatropin, somapacitan and somatrogon are added as examples of growth hormone analogues, which led to the reorganization and splitting of S2.2.3. 2 S6. Stimulants • S.6 Exceptions: Imidazole derivatives was changed to imidazoline derivatives to distinguish between generic imidazole derivatives and sympathomimetic imidazolines. • Cathine footnote: It was clarified that the urinary threshold of 5 µg/mL cathine refers to both isomers of norpseudoephedrine, i.e. the d-and the l-isomer (also referred to as 1S,2S- and 1R,2R- norpseudoephedrine, respectively). • Ethylphenidate, methylnaphthidate ((±)-methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate) and 4-fluoromethylphenidate are added to S6.b as examples of methylphenidate analogues. These substances have been prevalent in a number of countries over the past decade as they are often presented as alternatives to methylphenidate. • Hydrafinil (fluorenol) is added to S6.b as an example of modafinil and adrafinil analogue. S9. Glucocorticoids • Flucortolone is updated to its International Non-proprietary Name (INN), fluocortolone. • All injectable routes of administration are now prohibited for glucocorticoids during the In- Competition period. As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved at its 14-15 September 2020 meeting prohibition of all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This allows, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new minimum reporting levels (MRL), and sports authorities to develop educational tools for Athletes, medical and support personnel to address the safe use of glucocorticoids for clinical purposes and prevent doping. • For clarification, oral administration of glucocorticoids also includes oromucosal, buccal, gingival and sublingual routes. Dental-intracanal application is not prohibited. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 3 • Oral, intramuscular, rectal and intravenous routes were prohibited because there is clear evidence of systemic effects which could potentially enhance performance and be harmful to health. There are now also sufficient data available to show that the same systemic concentrations as existing prohibited routes can be achieved after administration by local injection (including periarticular, intra-articular, peritendinous and intratendinous) at licensed therapeutic doses. • The systemic plasma and hence urinary concentrations of glucocorticoids that are reached after administration by local injection using normal licensed therapeutic doses were demonstrated to reach levels consistent with doses that were shown to have the potential to improve performance in clinical studies. These levels are similar to, and even higher than, those obtained after other existing prohibited routes of administration of the same drug. The systemic effect of glucocorticoids following local injectable routes of administration may therefore present a significant potential to both improve performance and cause harm to health. Addition of local injections as prohibited routes Explanation of the approach taken • Glucocorticoids include naturally occurring hormones and synthetic analogues and possess a wide range of potencies and pharmacokinetic properties. The body naturally produces a daily output of the endogenous glucocorticoid (cortisol). However, administering glucocorticoid drugs can result in a total glucocorticoid exposure to the body that is much greater than the highest levels of normal physiological cortisol production, which could potentially be performance enhancing. • The administration of glucocorticoid medications by inhaled, or topical routes (including dental-intracanal, dermal, intranasal, ophthalmological and perianal), in accordance with the manufacturer’s approved dosing regimen, are unlikely to reach systemic concentrations which may be performance enhancing. • However, for other routes of administration (for example, oral), studies involving commonly used glucocorticoids at the normal therapeutic dose range indicated a performance-enhancing effect. These doses can be expressed in terms of cortisol-equivalents and thereby the dose which may be potentially performance enhancing for any glucocorticoid and route of administration can be determined using this approach. • This systematic approach was applied to determine the glucocorticoid routes of administration that are either prohibited or not prohibited in sport. Consequently, revised and substance-specific laboratory MRL based on excretion studies are introduced to better reflect the proposed approach. To note, the revised MRL are increased or remain unchanged for all glucocorticoids except triamcinolone acetonide, which was revised to a lower MRL. Overall, these changes should reduce the number of Adverse Analytical Findings reported by laboratories. 4 Washout periods following administration of glucocorticoids • Any injection of glucocorticoids is prohibited In-Competition. Given the widespread availability and the common use of glucocorticoids in sports medicine, Athletes and their Support Personnel are advised of the following: 1. Use of a glucocorticoid by injection during the In-Competition period requires a Therapeutic Use Exemption; otherwise, an alternative permitted medication in consultation with a physician shall be used. 2. After administration of glucocorticoids, urinary MRL which would result in an Adverse Analytical Finding can be reached for different periods of time after administration (ranging from days to weeks), depending on the glucocorticoid administered and the dose. To reduce the risk of an Adverse Analytical Finding, Athletes should follow the minimum washout periods*, expressed from the time of administration to the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). These washout periods are based on the use of these medications according to the maximum manufacturer’s licensed doses: Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone ace- tonide 30 days Intramuscular Betamethasone; dexametha- sone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections (including periarticular, intra-articular, peritendinous and intraten- dinous) All glucocorticoids; 3 days Except: triamcinolone ace- tonide; prednisolone; predni- sone 10 days * Washout period refers to the time from the last administered dose to the time of the start of the In- Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. 3. If the glucocorticoid needs to be administered via a prohibited route within these washout time periods, a Therapeutic Use Exemption (TUE) may be required. Physicians administering local injections of glucocorticoids should be aware that periarticular or intra-articular injection may sometimes inadvertently result in intramuscular administration. If intramuscular administration is suspected, the washout periods for the intramuscular route should be observed, or a TUE application sought. 5 P1. Beta-blockers • Underwater Sports (CMAS) subdisciplines were regrouped. This change does not affect the current subdisciplines where beta-blockers are prohibited. • For additional information including the revised MRL, please consult the recently published article with details of the process that lead to these changes: https://bjsm.bmj.com/content/ early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 4. Please note that as per Article 4.1e of the International Standard for TUEs, an Athlete may apply retroactively for a TUE if the Athlete Used Out-of-Competition, for therapeutic reasons, a Prohibited Substance that is only prohibited In-Competition. Athletes are strongly advised to have a medical file prepared and ready to demonstrate their satisfaction of the TUE conditions set out at Article 4.2, in case an application for a retroactive TUE is necessary following Sample collection. https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 6 • The monitoring of bemitil, and glucocorticoids is discontinued as the required prevalence data were obtained. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM https://www.wada-ama.org/en/questions-answers/prohibited-list-qa

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2022 Prohibited List S1. Anabolic Agents • Tibolone is transferred from S1.2 to S1.1 because it has clinical effects as a synthetic oral androgen mediated by effects on the androgen receptor, largely due to its conversion to the delta-4 tibolone metabolite, which is a potent androgen. • Osilodrostat, a CYP11B1 inhibitor, is added to S1.2 due to its off-target increase in circulating testosterone. S3. Beta-2 Agonists • The daily dosing time intervals for salbutamol are modified to 600 micrograms over 8 hours starting from the time any dose is taken (previously 800 micrograms over 12 hours). This is to reduce the risk of any potential Adverse Analytical Finding arising after high doses are taken at once. • The total permitted daily dose remains at 1600 micrograms over 24 hours. A Therapeutic Use Exemption (TUE) should be sought for doses in excess of these limits. • For example, an athlete could take 600 micrograms in the first 8 hours, 600 micrograms in the following 8 hours, and 400 micrograms in the remaining 8 hours of the day, without the need for a TUE. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. Non-approved Substances • BPC-157 is now prohibited under S0 following a recent re-evaluation and added as an example. S2. Peptide hormones, growth factors, related substances and mimetics • Lonapegsomatropin, somapacitan and somatrogon are added as examples of growth hormone analogues, which led to the reorganization and splitting of S2.2.3. 2 S6. Stimulants • S.6 Exceptions: Imidazole derivatives was changed to imidazoline derivatives to distinguish between generic imidazole derivatives and sympathomimetic imidazolines. • Cathine footnote: It was clarified that the urinary threshold of 5 µg/mL cathine refers to both isomers of norpseudoephedrine, i.e. the d-and the l-isomer (also referred to as 1S,2S- and 1R,2R- norpseudoephedrine, respectively). • Ethylphenidate, methylnaphthidate ((±)-methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate) and 4-fluoromethylphenidate are added to S6.b as examples of methylphenidate analogues. These substances have been prevalent in a number of countries over the past decade as they are often presented as alternatives to methylphenidate. • Hydrafinil (fluorenol) is added to S6.b as an example of modafinil and adrafinil analogue. S9. Glucocorticoids • Flucortolone is updated to its International Non-proprietary Name (INN), fluocortolone. • All injectable routes of administration are now prohibited for glucocorticoids during the In- Competition period. As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved at its 14-15 September 2020 meeting prohibition of all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This allows, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new minimum reporting levels (MRL), and sports authorities to develop educational tools for Athletes, medical and support personnel to address the safe use of glucocorticoids for clinical purposes and prevent doping. • For clarification, oral administration of glucocorticoids also includes oromucosal, buccal, gingival and sublingual routes. Dental-intracanal application is not prohibited. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 3 • Oral, intramuscular, rectal and intravenous routes were prohibited because there is clear evidence of systemic effects which could potentially enhance performance and be harmful to health. There are now also sufficient data available to show that the same systemic concentrations as existing prohibited routes can be achieved after administration by local injection (including periarticular, intra-articular, peritendinous and intratendinous) at licensed therapeutic doses. • The systemic plasma and hence urinary concentrations of glucocorticoids that are reached after administration by local injection using normal licensed therapeutic doses were demonstrated to reach levels consistent with doses that were shown to have the potential to improve performance in clinical studies. These levels are similar to, and even higher than, those obtained after other existing prohibited routes of administration of the same drug. The systemic effect of glucocorticoids following local injectable routes of administration may therefore present a significant potential to both improve performance and cause harm to health. Addition of local injections as prohibited routes Explanation of the approach taken • Glucocorticoids include naturally occurring hormones and synthetic analogues and possess a wide range of potencies and pharmacokinetic properties. The body naturally produces a daily output of the endogenous glucocorticoid (cortisol). However, administering glucocorticoid drugs can result in a total glucocorticoid exposure to the body that is much greater than the highest levels of normal physiological cortisol production, which could potentially be performance enhancing. • The administration of glucocorticoid medications by inhaled, or topical routes (including dental-intracanal, dermal, intranasal, ophthalmological and perianal), in accordance with the manufacturer’s approved dosing regimen, are unlikely to reach systemic concentrations which may be performance enhancing. • However, for other routes of administration (for example, oral), studies involving commonly used glucocorticoids at the normal therapeutic dose range indicated a performance-enhancing effect. These doses can be expressed in terms of cortisol-equivalents and thereby the dose which may be potentially performance enhancing for any glucocorticoid and route of administration can be determined using this approach. • This systematic approach was applied to determine the glucocorticoid routes of administration that are either prohibited or not prohibited in sport. Consequently, revised and substance-specific laboratory MRL based on excretion studies are introduced to better reflect the proposed approach. To note, the revised MRL are increased or remain unchanged for all glucocorticoids except triamcinolone acetonide, which was revised to a lower MRL. Overall, these changes should reduce the number of Adverse Analytical Findings reported by laboratories. 4 Washout periods following administration of glucocorticoids • Any injection of glucocorticoids is prohibited In-Competition. Given the widespread availability and the common use of glucocorticoids in sports medicine, Athletes and their Support Personnel are advised of the following: 1. Use of a glucocorticoid by injection during the In-Competition period requires a Therapeutic Use Exemption; otherwise, an alternative permitted medication in consultation with a physician shall be used. 2. After administration of glucocorticoids, urinary MRL which would result in an Adverse Analytical Finding can be reached for different periods of time after administration (ranging from days to weeks), depending on the glucocorticoid administered and the dose. To reduce the risk of an Adverse Analytical Finding, Athletes should follow the minimum washout periods*, expressed from the time of administration to the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). These washout periods are based on the use of these medications according to the maximum manufacturer’s licensed doses: Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone ace- tonide 30 days Intramuscular Betamethasone; dexametha- sone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections (including periarticular, intra-articular, peritendinous and intraten- dinous) All glucocorticoids; 3 days Except: triamcinolone ace- tonide; prednisolone; predni- sone 10 days * Washout period refers to the time from the last administered dose to the time of the start of the In- Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. 3. If the glucocorticoid needs to be administered via a prohibited route within these washout time periods, a Therapeutic Use Exemption (TUE) may be required. Physicians administering local injections of glucocorticoids should be aware that periarticular or intra-articular injection may sometimes inadvertently result in intramuscular administration. If intramuscular administration is suspected, the washout periods for the intramuscular route should be observed, or a TUE application sought. 5 P1. Beta-blockers • Underwater Sports (CMAS) subdisciplines were regrouped. This change does not affect the current subdisciplines where beta-blockers are prohibited. • For additional information including the revised MRL, please consult the recently published article with details of the process that lead to these changes: https://bjsm.bmj.com/content/ early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 4. Please note that as per Article 4.1e of the International Standard for TUEs, an Athlete may apply retroactively for a TUE if the Athlete Used Out-of-Competition, for therapeutic reasons, a Prohibited Substance that is only prohibited In-Competition. Athletes are strongly advised to have a medical file prepared and ready to demonstrate their satisfaction of the TUE conditions set out at Article 4.2, in case an application for a retroactive TUE is necessary following Sample collection. https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 6 • The monitoring of bemitil, and glucocorticoids is discontinued as the required prevalence data were obtained. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM https://www.wada-ama.org/en/questions-answers/prohibited-list-qa

COUNCIL OF EUROPE------------------ ---------------- CONSEIL DE L' EUROPE Strasbourg, 8 November 1988 DS-DO (88) Inf. 2 COMMITTEE FOR THE DEVELOPMENT OF SPORT Doping Definition of the Medical Commission of the IOC for the Olympic Winter and Summer Games 1988 (Calgary and Seoul) 19.096 04.8 THIS DOCUMENT WILL NOT BE DISTRIBUTED DURING THE MEETING PLEASE BRING THIS COPY Doping Definition of the Medical Commission of IOC for the Olympic Winter and Summer Games 1988 (Calgary and Seoul) List of Doping Classes and Methods I. DOPING CLASSES A. Stimulants B. Narcotics C. Anabolic Steroids D. Beta-Blockers E. Diuretics II. DOPING METHODS A. Blood Doping B. Pharmacological, Chemical and Physical Manipulations III. CLASSES OF DRUGS SUBJECT TO CERTAIN RESTRICTIONS A. Alcohol B. Local anaesthetics C. Corticosteroids NOTE: The doping definition of the IOC Medical Commission is based on the banning of pharmacological classes of agents. This definition has the advantage that also new drugs, some of which may be especially designed for doping purposes, are banned. The following list represents examples of the different dope classes to illustrate the doping definition. Unless indicated all substances belonging to the banned classes may not be used for medical treatment, even if they are not listed as examples. If substances of the banned classes are detected in the laboratory, the IOC Medical Commission will act. It should be noted that the presence of the drug in the urine constitutes an offence, irrespective of the route of administration. A. Stimulants e.g. amfepramone amfetaminil amiphenazole amphetamine benzphetamine caffeine* cathine chlorphentermine clobenzorex clorprenaline cocaine cropropamide (component of "micoren'') crotethamide (component of "micoren") dimetamfetamine ephedrine etafedrine etamivan etilamfetamine fencamfamin fenetylline fenproporex furfenorex mefenorex methamphetamine methoxyphenamine methylephedrine methylphenidate morazone nikethamide pemoline pentetrazol phendimetrazine phenmetrazine phentermine phenylpropanolamine pipradrol prolintane propylhexedrine pyrovalerone strychnine and related compounds * For caffeine the definition of a positive depends upon the following: - if the concentration in urine exceeds 12 micrograms/ml Stimulants comprise various types of drugs which increase alertness, reduce fatigue and may increase competitiveness and hostility. Their use can also produce loss of judgement, which may lead to accidents to others in some sports. Amphetamine and related compounds have the most notorious reputation in producing problems in sport. Amphetamine and related compounds have the most notorious reputation in producing problems in sport. Some deaths of sportsmen have resulted even when normal doses have been used under conditions of maximum physical activity. There is no medical justification for the use of 'amphetamines' in sport. One group of stimulants is the ^ ephedrine is an example. In 9 increased blood flow. Adverse produces mental stimulation an " and headache, increased effects include elevated tremor. In lower doses, and irregular heart beat, v,.jrine phenylpropanolamine,lley l.g ephedrine, pseudoephedrine,. in Sold and hay fever norpseudoephedrine, are Eased in pharmacies and sometimesçdhÂïn oSÏÏ.5 Ä?1he need of a medical prescription. pEVER puRCHASED By THUS NO PRODUCT FOR USE IN C0^^' RF used WITHOUT FIRST A COMPETITOR OR GIVEN^qi^PHARMACIST THAT THE PRODUCT DOES NOTSSÄÄUs cuss. - Beta2-agonists • +.v,Q fratment of asthma andThe coice of medication m the ^^“problems. Some years ago, sssr.ru1s:.> pS£;'¿ IZTTi'li.'ST’«therefore considered as stimu an .... The use of the following beta2-agonists is permitted in aerosol form : bitolterol orciprenaline rimiterol salbutamol terbutaline. and B. Narcotics analgesics e.g. alphaprodine anileridine buprénorphine codeine dextromoramide dextropropoxyphen diamorphine (heroin) dihydrocodéine dipipanone ethoheptazine ethylmorphine levorphanol methadone morphine .. nalbuphine pentazocine pethidine phenazocine trimeperidine and related compounds The drugs belonging to this class, which are represented by morphine and its chemical and pharmacological analogs, act fairly specifically as analgesics for the management of moderate to severe pain. This description however by no means implies that their clinical effect is limited to the relief of trivial disabilities. Most of these drugs have major side effects, including doserelated respiratory depression, and carry a high risk of physical and psychological dependence. There exists evidence indication that narcotic analgesics have been and are abused in sports, and therefore the IOC Medical Commission has issued and maintain a ban on their use during the Olympic Games. The ban is also justified by international restrictions affecting the movement of these compounds and is in line with the regulations and recommendations of the World Health Organisation regarding narcotics. Furthermore, it is felt that the treatment of slight to moderate pain can be effective using drugs - other than the narcotics - which have analgesic, anti-inflammatory and antipyretic actions. Such alternatives, which have been successfully used for the treatment of sports injuries, include Anthranilic acid derivatives (such as Mefenamic acid, Floctafenine, Glafenine, etc.), Phenylalkanoic acid derivatives (such as Diclofenac, Ibuprofen, Ketoprofen, Naproxen, etc.) and compounds such as Indomethacin and Sulindac. The Medical Commission also reminds athletes and team doctors that Aspirin and its newer derivatives (such as Diflunisal) are not banned but cautions against some pharmaceutical preparations where Aspirin is often associated to a banned drug such as Codeine. The same precautions hold for cough and cold preparations which often contain drugs of the banned classes. NOTE: DEXTRMETHORPHAN IS NOT BANNED AND MY BE USED AS AN ANTI­ TUSSIVE DIPHENOXYLATE IS ALSO PERMITTED C. Anabolic steroids e.g. bolasterone boldenone clostebol dehydrochlormethyltestosterone fluoxyxnesterone mesterolone xnetandienone metenolone methyltestosterone nandrolone norethandrolone oxandrolone oxymesterone oxymetholone stanozolol testosterone* and related compunds ♦Testosterone: the definition of a positive depends upon the following - the administration of testosterone or the use of any other manipulation having the result of increasing the ratio in urine of testosterone/epitestosteorne to above 6. It is well known that the administration to males of Human Chorionic Gonadotrophine (HCG) and other compounds with related activity leads to an increased rate of production of androgenic steroids. The use of these substances is therefore banned. This class of drugs includes chemicals which are related in structure and activity to the male hormone testosterone, which is also included in this banned class. They have been misused in sport, not only to attempt to increase muscle bulk, strength and power when used with increased food intake, but also in lower doses and normal food intake to attempt to improve competitiveness. Their use in teenagers who have not fully developed can result in stunting growth by affecting growth at the ends of the long bones. Their use can produce psychological changes, liver damage and adversely affect the blood lipids and the cardio-vascular system. In males, their use can reduce testicular size and sperm production; in females, their use can produce masculinisation, acne, development of male pattern hair growth and suppression of ovarian function and menstruation. D. Beta-blockers e.g. acébutolol alprenolol atenolol labetalol metoprolol nadolol oxprenolol propranolol sotalol and related compounds The IOC Medical Commission has reviewed the therapeutic indications for the use of beta-blocking drugs and noted that there is now a wide range of effective alternative preparations available in order to control hypertension, cardiac arrhythmias, angina pectoris and migraine. Due to the continued misuse of beta-blockers in some sports where physical activity is of no or little importance, the IOC Medical Commission reserves the right to test those sports, which it deems appropriate. These are unlikely to include endurance events which necessitate prolonged periods of high cardiac output and large stores of metabolic substrates in which beta-blockers would severely decrease performance capacity. E. Diuretics e.g. acetazolamide amiloride bendroflumethiazide benzthiazide bumetanide canrenone chlormerodrin chlortalidone diclofenamide ethacrynic acid furosemide hydrochlorothiazide mersalyl spironolactone triamterene and related compounds. Diuretics have important therapeutic indications for the elimination of fluids from the tissues in certain pathological conditions. However, strict medical control is required. Diuretics are sometimes misused by competitors for two main reasons, namely: to reduce weight quickly in sports where weight categories are involved and to reduce the concentration of drugs in urine by producing a more rapid excretion of urine to attempt to minimise detection of drug mususe. Rapid reduction of weight in sport cannot be justified medically. Health risks are involved in such misuse because of serious side-effects which might occur. Furthermore, deliberate attempts to reduce weight artificially in order to compete in lower weight classes or to dilute urine constitute clear manipulations which are unacceptable on ethical grounds. Therefore, the IOC Medical Commission has decided to include diuretics on its list of banned classes of drugs. N.B. For sports involving weight classes, the IOC Medical Commission reserves the right to obtain urine samples from the competitor at the time of the weighing. II. Methods A. Blood doping Blood transfusion is the intravenous administrate of red blood cells or related blood products that contain red blood cells. Such products can be obtained from blood drawn form the same (autologous) or from a different (non-autologous) individual. The most commond indications for red blood transfusion in conventional medical practice are acute blood loss and severe anaemia. Blood doping is the administration of blood or related red blood products to an athlete other than for legitimate medical treatment. This procedure may be preceeded by withdrawal of blood from the athlete who continues to train in this blood depleted state. These procedures contravene the ethics of medicine and of sport. There are also risks involved in the transfusion of blood and related blood products. These include the development of allergic reactions with (rash, fever etc.) and acute haemolytic reaction with kidney damage if incorrectly typed blood is used, as well as delayed transfusion reaction resulting in fever and jaundice, transmission of infectious diseases (viral hepatitis and AIDS), overload of the circulation and metabolic shock. Therefore the practice of blood doping in sport is banned by the IOC Medical Commission. B. Pharmacological, Chemical and Physical Manipulations The IOC Medical Commission bans the use of substances and of methods which alter the integrity and validity of urine samples used in doping controls. Examples of banned methods are catheterisation, urine substitution and/or tappering, inhibition of renal excretion, e.g. by probenecide and related compounds. III. CLASSES OF DRUGS SUBJECT TO CERTAIN RESTRICTIONS A. Alcohol Alcohol is not prohibited. However breath or blood alcohol levels may be determined at the request of an International Federation. B. Local anaesthetics Injectable local anaesthetics are permitted under the following conditions : a) that procaine, xylocaine, carbocaine, etc. are used but not cocaine; b) only local or intraarticular injections may be administered; c) only when medically justified (i.e. the details including diagnosis, dose and route of adminstration must be submitted immediately in writing to the IOC Medical Commission). C. Corticosteroids The naturally occurring and synthetic corticosteroids are mainly used as anti-inflammatory drugs which also relieve pain. These drugs influence circulating concentrations of natural corticosteroids in the body. They produce euphoria and side- effects such that their medical use, except when used topically, require medical control. Since 1975, the IOC Medical Commission has attempted to restrict their use during the Olympic Games by requiring a declaration by the team doctors because it was known that corticosteroids were being used non-therapeutically by the oral, intramuscular and even the intravenous route in some sports. However, the problem was not solved by these restrictions and therefore stronger measures designed not to interfere with the appropriate medical use of these compounds became necessary. The use of corticosteroids is banned except for topical use (aural, ophthalmological and dermatological), inhalational therapy (asthma, allergic rhinitis) and local or intra-articular injections. ANY TEAM DOCTOR WISHING TO ADMINISTER CORTICOSTEROIDS INTRA- ARTICULARLY OR LOCALLY TO A COMPETITOR MUST GIVE WRITTEN NOTIFICATION TO THE IOC MEDICAL COMMISSION.

[image: ][image: ] Teilnehmende für Long-COVID-Studie gesucht Helfen Sie mit, Long COVID besser zu verstehen! Long COVID betrifft viele Menschen und kann mit vielfältigen, teils stark belastenden Beschwerden einhergehen. Da die Ursachen und zugrunde liegenden Mechanismen bislang nicht vollständig verstanden sind, ist weitere Forschung notwendig, um die Erkrankung besser zu verstehen und Behandlungsansätze gezielt zu verbessern. Für eine wissenschaftliche Studie an der Deutschen Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, suchen wir daher interessierte Teilnehmerinnen und Teilnehmer — mit und ohne Long COVID. Worum geht es in der Studie? Wir untersuchen, wie sich körperliche Belastung auf die Sauerstoffversorgung und Sauerstoffverwertung des Muskelgewebes sowie auf die autonome Regulation des Körpers auswirkt. Wer kann teilnehmen? Männer und Frauen > 18 Jahre, unabhängig davon, ob eine Long-COVID-Erkrankung vorliegt oder nicht. Was erwartet Sie? Die Untersuchung umfasst: · standardisierte Fragebögen · einen Ein-Minuten-Sitz-Steh-Test · einen Belastungstest auf dem Fahrradergometer Ort und Dauer Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung molekulare und zelluläre Sportmedizin Dauer: ca. 1 Stunde Aufwandsentschädigung Sie erhalten 10 € pro Stunde. Interesse? Dann melden Sie sich gerne bei: Anna-Lena Krüger E-Mail: krueger@sportinstitut.net image1.png © S.P.0.R.T INSTITUT image2.png Deutsche Sporthochschule K6éln German Sport University Cologne

Teilnehmende für Long-COVID-Studie gesucht Helfen Sie mit, Long COVID besser zu verstehen! Long COVID betrifft viele Menschen und kann mit vielfältigen, teils stark belastenden Beschwerden einhergehen. Da die Ursachen und zugrunde liegenden Mechanismen bislang nicht vollständig verstanden sind, ist weitere Forschung notwendig, um die Erkrankung besser zu verstehen und Behandlungsansätze gezielt zu verbessern. Für eine wissenschaftliche Studie an der Deutschen Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, suchen wir daher interessierte Teilnehmerinnen und Teilnehmer — mit und ohne Long COVID. Worum geht es in der Studie? Wir untersuchen, wie sich körperliche Belastung auf die Sauerstoffversorgung und Sauerstoffverwertung des Muskelgewebes sowie auf die autonome Regulation des Körpers auswirkt. Wer kann teilnehmen? Männer und Frauen > 18 Jahre, unabhängig davon, ob eine Long-COVID-Erkrankung vorliegt oder nicht. Was erwartet Sie? Die Untersuchung umfasst: • standardisierte Fragebögen • einen Ein-Minuten-Sitz-Steh-Test • einen Belastungstest auf dem Fahrradergometer Ort und Dauer Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung molekulare und zelluläre Sportmedizin Dauer: ca. 1 Stunde Aufwandsentschädigung Sie erhalten 10 € pro Stunde. Interesse? Dann melden Sie sich gerne bei: Anna-Lena Krüger E-Mail: krueger@sportinstitut.net mailto:krueger@sportinstitut.net

Checkliste für Ihre Bewerbung M.Sc. Sport, Bewegung und Ernährung Was ist allgemein zu beachten? Bewerbung nur über das Bewerbungsportal mySpoho einreichen. Alle Dokumente müssen im PDF-Format vorliegen. Urkunden, Zeugnisse etc. müssen stets alle Seiten enthalten, die sie im Original haben. Beglaubigte Übersetzungen werden benötigt, wenn das Hochschulzeugnis im Original nicht in Deutsch oder Englisch ist. Korrekte Dateinamen: Benennen Sie Ihre PDF-Dateien wie in der Checkliste beschrieben. Welche Dokumente werden benötigt? Dokument Dateiname Hinweis Nachweis Studium mit mindestens 180 ECTS Studienabschluss_Name.pdf Der Nachweis des Studienabschlusses muss folgende Unterlagen enthalten: • Urkunde im Original • Zeugnisurkunde im Original • Notenübersicht („ToR“ - Transcript of Records im Original) Nachweis Berufserfahrung im Bereich Sport, Bewegung oder Ernährung Berufserfahrung_Name.pdf Der Nachweis über die einjährige Berufserfahrung muss folgende Angaben enthalten: • Zeitraum der Tätigkeit (von – bis) • Wochenarbeitszeit (mind. 20 Stunden pro Wochen) • Beschreibung der Tätigkeit • Name und Funktion der ausstellenden Person • Datum und Unterschrift der ausstellenden Stelle • offizielles Geschäftspapier Ein Arbeitsvertrag kann als Nachweis nicht anerkannt werden. Nachweis der Sporttauglichkeit Sporttauglichkeit_Name.pdf Aktuelles ärztliches Attest, das ausdrücklich bestätigt, dass die gesundheitliche Eignung für sportliche Belastungen im Rahmen des Studiums des M.Sc. Sport, Bewegung und Ernährung besteht. Tabellarischer Lebenslauf Lebenslauf_Name.pdf Tabellarischer Lebenslauf (1–2 Seiten) mit aussagekräftigen Angaben zur beruflichen Erfahrung. Checkliste für Ihre Bewerbung M.Sc. Sport, Bewegung und Ernährung ggf. Nachweis extern erbrachter Leistungen ExterneLeistungen_Name.pdf Die Nachweise über die Weiterbildungen müssen folgende Angaben enthalten: • Zeitraum der Tätigkeit (von – bis) • Anzahl der Unterrichtseinheiten / Stunden • Beschreibung der Tätigkeit • Name und Funktion der ausstellenden Person • Datum und Unterschrift der ausstellenden Stelle • offizielles Vereins- oder Geschäftspapier Bei umfangreichen Nachweisen zu extern erbrachten Leistungen fügen Sie bitte eine kurze Übersicht als Deckblatt bei. Diese sollte die einzelnen Nachweise stichwortartig aufführen, z. B. „Training am Gerät“, „Übungsleiter B Breitensport“, „Weiterbildung XY“ oder „Symposiumsbeitrag“. Beispiele möglicher anerkannter Leistungen finden Sie im Anrechnungskatalog. ggf. Nachweis Sprachkenntnisse Sprachzertifikat_Name.pdf Deutsch-Niveau C1 (oder höher). Nur für internationale Bewerber*innen. Bitte beachten Sie, dass unvollständige Bewerbungsunterlagen nicht berücksichtigt werden können und dazu führen können, dass Sie keinen Studienplatz angeboten bekommen.